Abstract

Samia A. Ahmed, Wessam M. Aziz, Omar S. Omar, Noha Nabil and Manal A. Hamed*

ABSTRACT

Breast cancer (BC) and ovarian cancer (OC) are the most developed malignancies in women worldwide. The goal of this study was to explore the role of certain biomarkers to predict prognosis in breast and ovarian malignancies. The research was expanded to determine the efficacy of these measures as differential factors in illness progression as well as their diagnostic specificity. Eighty females were enrolled in this study. They classified into BC, OC and healthy women. The BC and OC groups were subdivided into early cancer stage, late cancer stage of grade 2 and late cancer stage of grade 3. Cluster of differentiation 31 (CD31), vitronectin (VTN), regulated on activation normal T cell expressed and secreted (RANTES) and lysosomal-associated transmembrane protein 4? (LAPTM4?) biomarkers were estimated in all groups. The results revealed significant increase in CD31, RANTES and LAPTM4B in all stages of BC and a significant increase in VTN in the early stage of BC. Conversely, a significant decrease in CD31 and VTN in all stages of OC and slightly increases in RANTES in late stages of OC, while non-significant change was observed in the early stage. LAPTM4B showed significant increase in all stages of OC compared with the healthy women. In conclusion, vitronectin, LAPTM4B and RANTES may be considered as prognostic and diagnostic markers in BC with special emphasis to VTN as a promising marker in the early stage of BC. In addition, LAPTM4B seems to be a prognostic and diagnostic marker for OC. For the limited numbers of patients, more supportive studies are needed to confirm the efficacy and specificity of these biomarkers in prognosis or diagnosis of BC and OC.